MigVax-101

MigVax-101
Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Routes of; administration	Oral

MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.^[1]^[2]^[3]

References[]

^ Jaffe-Hoffman M (11 June 2021). "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. Retrieved 2 November 2021.
^ Jaffe-Hoffman M (22 July 2021). "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. Retrieved 2 November 2021.
^ "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. Retrieved 2 November 2021.

Scholia has a profile for MigVax-101 (Q110269796).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by .

This article about vaccines or vaccination is a stub. You can help Wikipedia by .

[1] Jaffe-Hoffman M (11 June 2021). "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. Retrieved 2 November 2021.

[2] Jaffe-Hoffman M (22 July 2021). "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. Retrieved 2 November 2021.

[3] "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. Retrieved 2 November 2021.

[1]

[2]

[3]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Evacuations Face masks International aid Investigations into origin Living with COVID-19 Lockdowns by country Misinformation by governments Fake treatments Protests Software Travel restrictions United Nations World Health Organization WTO IP waiver Undercounting of deaths Zero-COVID National responses Africa China European Union Germany Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Vaccine candidates CoronaVac Covaxin Convidecia Janssen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Sports Television Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US
Impacts Animals Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t